These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2852947)

  • 21. Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study.
    Thompson DS; Hainsworth JD; Hande KR; Holzmer M; Greco FA
    Cancer; 1994 Jun; 73(11):2824-31. PubMed ID: 8194024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of the variability of etoposide pharmacokinetics in children.
    Boos J; Real E; Schulze-Westhof ; Wolff J; Euting T; Jürgens H
    Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):495-7. PubMed ID: 1490803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer.
    Kunitoh H; Watanabe K
    J Clin Oncol; 1994 Jan; 12(1):83-9. PubMed ID: 8270989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination chemotherapy with cisplatin, etoposide and gallium chloride for lung cancer: individual adaptation of doses.
    Collery P; Morel M; Desoize B; Millart H; Perdu D; Prevost A; Vallerand H; Pechery C; Choisy H; Etienne JC
    Anticancer Res; 1991; 11(4):1529-32. PubMed ID: 1660690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of high-dose etoposide after short-term infusion.
    Köhl P; Köppler H; Schmidt L; Fritsch HW; Holz J; Pflüger KH; Jungclas H
    Cancer Chemother Pharmacol; 1992; 29(4):316-20. PubMed ID: 1537079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE
    J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. SDZ ILE 964 (IL-3) Study.
    Kudoh S; Sawa T; Kurihara N; Furuse K; Kurita Y; Fukuoka M; Takada M; Takaku F; Ogawa M; Ariyoshi Y
    Cancer Chemother Pharmacol; 1996; 38 Suppl():S89-95. PubMed ID: 8765425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacokinetics of high dose cyclophosphamide and high dose etoposide.
    Cunningham D; Cummings J; Blackie RB; McTaggart L; Banham SW; Kaye SB; Soukop M
    Med Oncol Tumor Pharmacother; 1988; 5(2):117-23. PubMed ID: 2842552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study and clinical pharmacological evaluation of daily oral etoposide combined with carboplatin in patients with lung cancer.
    Ohune T; Fujiwara Y; Sumiyoshi H; Yamaoka N; Yamakido M
    Jpn J Cancer Res; 1995 May; 86(5):490-500. PubMed ID: 7790322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors.
    Kreis W; Budman DR; Vinciguerra V; Hock K; Baer J; Ingram R; Schacter LP; Fields SZ
    Cancer Chemother Pharmacol; 1996; 38(4):378-84. PubMed ID: 8674162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
    Robert F; Chen S; Miller AA; Lee BC; Molthrop DC; Wheeler RH
    Cancer Chemother Pharmacol; 1996; 38(5):459-65. PubMed ID: 8765440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
    Budman DR; Igwemezie LN; Kaul S; Behr J; Lichtman S; Schulman P; Vinciguerra V; Allen SL; Kolitz J; Hock K
    J Clin Oncol; 1994 Sep; 12(9):1902-9. PubMed ID: 8083713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.
    Slevin ML; Clark PI; Joel SP; Malik S; Osborne RJ; Gregory WM; Lowe DG; Reznek RH; Wrigley PF
    J Clin Oncol; 1989 Sep; 7(9):1333-40. PubMed ID: 2549204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408.
    Fujishiro M; Shinkai T; Fukuda M; Tamura T; Ohe Y; Kunitoh H; Nishiwaki Y; Sekine I; Fukuda H; Saijo N
    Jpn J Clin Oncol; 2000 Nov; 30(11):487-93. PubMed ID: 11155918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
    Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
    J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study.
    Grunberg SM; Crowley J; Hande KR; Giroux D; Munshi N; Lau DH; Schroder LE; Zangmeister MH; Balcerzak SP; Hynes HE; Gandara DR
    Cancer Chemother Pharmacol; 1999; 44(6):461-8. PubMed ID: 10550566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.